Ashley Kathryn McCulloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley Kathryn McCulloch has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Campbell Stuart Roxburgh
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
13 shared publications - Séan Micheal O'Cathail
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
13 shared publications - Joanne Edwards
University of Glasgow
12 shared publications - Lily Victoria Sarah Hillson
University of Glasgow 1 School of Cancer Sciences, Wolfson Wohl Cancer Research Centre Glasgow, United Kingdom
11 shared publications - Kathryn A. F. Pennel
School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK
10 shared publications - Philip David Dunne
Queens University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, UK
10 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226
IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer
- 24 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226
Open AccessIAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer
- Open Access
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1705-1714
Immune and stromal tumour biology associated with neoadjuvant radiotherapy response in locally advanced rectal cancer
Background: Response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (LARC) is heterogeneous. The Neoadjuvant Rectal (NAR) score quantifies treatment response via tumour downstaging and nodal status and correlates with survival outcomes. This work set out to explore whether low NAR and high NAR tumours represent biologically distinct groups pre-treatment. Methods: Transcriptome microarrays quantified RNA expression within pre-treatment biopsies from LARC patients in GSE87211 and S:CORT consortium Grampian datasets. A validation cohort from the Beatson West of Scotland Cancer Centre was analysed using multiplex immunofluorescence and H&E-derived tumour-stromal ratios. Results: Seventeen MSigDB Hallmarks were enriched in high NAR tumours; ‘Epithelial-Mesenchymal Transition’ was notably enriched (padj < 0.001). Immune-related signatures were enriched in low NAR tumours ( p < 0.25). Both cohorts showed higher Microenvironment Cell Population counter ‘Cytotoxic Lymphocytes’ in low NAR ( p < 0.05) and more stromal cells (‘Endothelial Cells’, ‘Fibroblasts’; p < 0.05) in high NAR tumours. CD8 densities confirmed higher immune infiltration in low NAR tumours. Discussion: Pre-treatment biopsies show consistent microenvironmental differences between high and low NAR tumours. While immune and stromal features are associated with response, the observed differences are insufficient to serve as standalone predictive biomarkers.
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1705-1714
Open AccessImmune and stromal tumour biology associated with neoadjuvant radiotherapy response in locally advanced rectal cancer
Background: Response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (LARC) is heterogeneous. The Neoadjuvant Rectal (NAR) score quantifies treatment response via tumour downstaging and nodal status and correlates with survival outcomes. This work set out to explore whether low NAR and high NAR tumours represent biologically distinct groups pre-treatment. Methods: Transcriptome microarrays quantified RNA expression within pre-treatment biopsies from LARC patients in GSE87211 and S:CORT consortium Grampian datasets. A validation cohort from the Beatson West of Scotland Cancer Centre was analysed using multiplex immunofluorescence and H&E-derived tumour-stromal ratios. Results: Seventeen MSigDB Hallmarks were enriched in high NAR tumours; ‘Epithelial-Mesenchymal Transition’ was notably enriched (padj < 0.001). Immune-related signatures were enriched in low NAR tumours ( p < 0.25). Both cohorts showed higher Microenvironment Cell Population counter ‘Cytotoxic Lymphocytes’ in low NAR ( p < 0.05) and more stromal cells (‘Endothelial Cells’, ‘Fibroblasts’; p < 0.05) in high NAR tumours. CD8 densities confirmed higher immune infiltration in low NAR tumours. Discussion: Pre-treatment biopsies show consistent microenvironmental differences between high and low NAR tumours. While immune and stromal features are associated with response, the observed differences are insufficient to serve as standalone predictive biomarkers.
- Open Access
Epithelial Stem Cell Fate Determines Chemoradiotherapy Response in Rectal Cancer
SUMMARY: Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy. HIGHLIGHTS: Rectal cancer stem cell-fate determines chemoradiotherapy-induced apoptosis proCSCs retain DNA-damage and die, whereas revCSCs repair damage and persist CAFs and chemoradiotherapy converge on a common chemo-radioresistant revCSC state SPARTA reveals TEAD inhibition blocks DNA-repair persisters in stromal assembloids
Open AccessEpithelial Stem Cell Fate Determines Chemoradiotherapy Response in Rectal Cancer
SUMMARY: Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy. HIGHLIGHTS: Rectal cancer stem cell-fate determines chemoradiotherapy-induced apoptosis proCSCs retain DNA-damage and die, whereas revCSCs repair damage and persist CAFs and chemoradiotherapy converge on a common chemo-radioresistant revCSC state SPARTA reveals TEAD inhibition blocks DNA-repair persisters in stromal assembloids
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Study representativeness table